Literature DB >> 23249236

Recent progress in canine tumor vaccination: potential applications for human tumor vaccines.

Sofie Denies1, Niek N Sanders.   

Abstract

Tumor vaccination holds great promise for the treatment of cancer and research concerning tumor vaccination in dogs is of great interest for veterinary as well as human medicine. Indeed, cancer is the leading cause of death in adult dogs and companion animals are acknowledged as excellent preclinical models for human oncology. The license of the veterinary melanoma vaccine (Oncept™) and Provenge® for the treatment of prostate cancer in men established tumor vaccination as a valid treatment modality for cancer. Although the results with this and other vaccines are promising, there are still some hurdles to overcome. In this article, preclinical and clinical trials with tumor vaccines in dogs are discussed, as well as the surplus value of canine cancer patients for human medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23249236     DOI: 10.1586/erv.12.104

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  3 in total

Review 1.  Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

Authors:  Vladimir L Gabai; Victor I Shifrin
Journal:  Int Rev Immunol       Date:  2014-10       Impact factor: 5.311

2.  Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector.

Authors:  Franco Venanzi; Victor Shifrin; Michael Sherman; Vladimir Gabai; Oleg Kiselev; Andrey Komissarov; Mikhail Grudinin; Maria Shartukova; Ekaterina A Romanovskaya-Romanko; Yuri Kudryavets; Natalya Bezdenezhnykh; Oleksandra Lykhova; Nadiia Semesyuk; Antonio Concetti; Anatoly Tsyb; Marina Filimonova; Victoria Makarchuk; Raisa Yakubovsky; Andrey Chursov; Vita Shcherbinina; Alexander Shneider
Journal:  Oncotarget       Date:  2013-10

3.  Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity.

Authors:  Jamie F S Mann; Paul F McKay; Katja Klein; Joshua Pankrac; John S Tregoning; Robin J Shattock
Journal:  Immunology       Date:  2021-12-12       Impact factor: 7.215

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.